SMORE-DRL: Scalable Multi-Objective Robust and Efficient Deep Reinforcement Learning for Molecular Optimization

27 Sept 2024 (modified: 25 Nov 2024)ICLR 2025 Conference Withdrawn SubmissionEveryoneRevisionsBibTeXCC BY 4.0
Keywords: Drug Design, Molecular Optimization, Deep Reinforcement Learning, Multi-Objective Optimization, Transformer, Scalable
Abstract: The adoption of machine learning techniques within the domain of drug design provides an opportunity of systematic and efficient exploration of the vast chemical search space. In recent years, advancements in this domain have been achieved through the application of deep reinforcement learning (DRL) frameworks. However, the scalability and performance of existing methodologies are constrained by prolonged training periods and inefficient sample data utilization. Furthermore, generalization capabilities of these models have not been fully investigated. To overcome these limitations, we take a multi-objective optimization perspective and introduce SMORE-DRL, a fragment and transformer-based multi-objective DRL architecture for the optimization of molecules across multiple pharmacological properties, including binding affinity to a cancer protein target. Our approach involves pretraining a transformer-encoder model on molecules encoded by a novel hybrid fragment-SMILES representation method. Fine-tuning is performed through a novel gradient-alignment-based DRL, where lead molecules are optimized by selecting and replacing their fragments with alternatives from a fragment dictionary, ultimately resulting in more desirable drug candidates. Our findings indicate that SMORE-DRL is superior to current DRL models for lead optimization in terms of quality, efficiency, scalability, and robustness. Furthermore SMORE-DRL demonstrates the capability of generalizing its optimization process to lead molecules that are not present during the pretraining or fine-tuning phases.
Primary Area: applications to physical sciences (physics, chemistry, biology, etc.)
Code Of Ethics: I acknowledge that I and all co-authors of this work have read and commit to adhering to the ICLR Code of Ethics.
Submission Guidelines: I certify that this submission complies with the submission instructions as described on https://iclr.cc/Conferences/2025/AuthorGuide.
Reciprocal Reviewing: I understand the reciprocal reviewing requirement as described on https://iclr.cc/Conferences/2025/CallForPapers. If none of the authors are registered as a reviewer, it may result in a desk rejection at the discretion of the program chairs. To request an exception, please complete this form at https://forms.gle/Huojr6VjkFxiQsUp6.
Anonymous Url: I certify that there is no URL (e.g., github page) that could be used to find authors’ identity.
No Acknowledgement Section: I certify that there is no acknowledgement section in this submission for double blind review.
Submission Number: 12238
Loading